

October 2025 Content Release Notes

October 23, 2025

Contents

Clinical Profile Documentation	2
Additions.....	2
Problem Groups.....	4
Additions.....	4
Problems.....	4
Additions.....	4
Lab Analytes & Panels	5
Medications.....	7
Additions.....	7
Updates.....	8
Regimen Library.....	12
Additions.....	12
Updates.....	15
Biosimilar Precheck Changes	15
Renames	16
Removals	17
NDC – HCPCS Crosswalk	17
Additions.....	17
Billing & HCPCS Codes	18
Updates.....	18
Appendix A.....	19
SCRI Medication Updates	19

Clinical Profile Documentation

Additions

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses.

Fallopian Tube Cancer Histopathologic Type has been updated for **Fallopian Tube Cancer** with the following documentation points:

- Serous epithelial
- Serous epithelial (high grade)
- Serous epithelial (low grade)
- Mucinous adenocarcinoma epithelial
- Endometrioid epithelial
- Clear cell epithelial
- Transitional cell/Brenner's epithelial
- Mixed epithelial
- Squamous cell epithelial
- Undifferentiated epithelial
- Dysgerminoma, germ cell
- Endodermal sinus tumor-germ cell
- Choriocarcinoma, germ cell
- Immature teratoma-germ cell
- Embryonal, germ cell
- Gonadoblastoma-germ cell
- Polyembryoma
- Mixed germ cell tumor
- Granulosa cell tumor-sex cord stromal
- Sertoli-Leydig-sex cord stromal
- Sertoli cell-sex cord stromal
- Sex cord tumor with annular tubules-sex cord stromal
- Steroid cell
- Leydig or hilar cell tumor-steroid cell
- Small cell carcinoma
- Non-small cell carcinoma
- Malignant mixed mullerian tumor
- Squamous cell

- Mature teratoma with malignancy
- Undifferentiated
- Unclassified
- Other
- Unknown

Human papillomavirus (HPV) p16 status is now available for **Oropharyngeal Cancer** with the following documentation points:

- Positive
- Negative
- Unknown

IDH2 status is now available for **Myelodysplastic Syndrome (MDS)** with the following documentation points:

- Mutation
- Wild type
- Other non-actionable finding
- Unknown

RET fusion status is now available for **Uterine Cancer (Parent)** with the following documentation points:

- Positive
- Negative
- Other non-actionable finding
- Unknown

Problem Groups

Additions

The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.

Problem	ICD-10 Codes
Chronic myelomonocytic leukemia (disorder)	C93.10 - Chronic myelomonocytic leukemia not having achieved remission
Participating in clinical research study (finding)	Z00.6 - Encounter for examination for normal and control clinical research program

Problems

Additions

New items are available for documentation in **Problems** and appear in the **Charge Capture Report (CCR)**. Additional ICD-10 codes* may be displayed to present the surrounding nodes.

Please see [Appendix A](#) for a complete summary of changes.

Lab Analytes & Panels

This release includes monthly updates to laboratory test content. New tests have been added, and existing tests were reviewed and updated to ensure alignment with current clinical standards. These updates include refinements to test names, synonyms, and panel structures to support accurate ordering, reporting, and interoperability across systems.

- Anti-68kD (hsp 70) Abs, qual
- Anti-La (SS-B) Ab (RDL), units
- Anti-Ro (SS-A) Ab (RDL), units
- Bone marrow morphologic panel
- Bone marrow morphology additional notation
- Bone marrow morphology aspirate/imprint
- Bone marrow morphology body site
- Bone marrow morphology bone marrow biopsy clot
- Bone marrow morphology bone marrow biopsy core
- Bone marrow morphology bone marrow differential count
- Bone marrow morphology client specimen id
- Bone marrow morphology clinical summary and indication
- Bone marrow morphology comment
- Bone marrow morphology container(s) received
- Bone marrow morphology diagnosis
- Bone marrow morphology disclaimer
- Bone marrow morphology electronically signed by
- Bone marrow morphology gross description
- Bone marrow morphology immunohistochemistry
- Bone marrow morphology peripheral blood
- Bone marrow morphology peripheral smear review
- Bone marrow morphology proxy release by
- Bone marrow morphology referring physician
- Bone marrow morphology reviewing pathologist
- Bone marrow morphology revision text
- Bone marrow morphology specimen type
- Bone marrow morphology test(s) canceled
- Bone marrow morphology treating physician
- Cobalt, blood panel
- Cobalt, serum panel
- Cortisol post cortrosyn panel

- Cortisol post cortrosyn, mcg/dL
- DNA double stranded Ab, IgG, S
- Flow cytometry CP additional notation
- Flow cytometry CP body site
- Flow cytometry CP cell distribution
- Flow cytometry CP cell distribution description
- Flow cytometry CP client specimen ID
- Flow cytometry CP clinical summary and indication
- Flow cytometry CP comments
- Flow cytometry CP container(s) received
- Flow cytometry CP disclaimer
- Flow cytometry CP electronically signed by
- Flow cytometry CP gross description
- Flow cytometry CP interpretation
- Flow cytometry CP morphology
- Flow cytometry CP panel
- Flow cytometry CP phenotype
- Flow cytometry CP processed date
- Flow cytometry CP proxy released by
- Flow cytometry CP referring physician
- Flow cytometry CP results
- Flow cytometry CP reviewing pathologist
- Flow cytometry CP revision text
- Flow cytometry CP specimen type
- Flow cytometry CP test(s) cancelled
- Flow cytometry CP treating physician
- Flow cytometry CP viability and abnormal cells
- Foundation medicine MMR (MLH1, MSH2, MSH6, PMS2) panel
- FoundationOne germline panel
- Ganglioside IgG autoantibody panel
- HSV 2 IgG inhibition, IA
- HSV 2 IgG inhibition, IA panel
- Natera empower it panel
- Natera signatera kit panel
- Tempus familial variant/single site analysis standard panel
- Tempus purist standard panel
- Tempus xF + liquid biopsy amendment panel
- Tempus xG (common hereditary cancers) 52 gene amendment panel

- Tempus xG CancerNext + RNAinsight standard panel
- Tempus XG CancerNext amendment panel
- Tempus XG CancerNext standard panel
- Tempus xG plus CancerNext expanded + RNA insight amendment panel
- Tempus xG+ (CancerNext expanded) +RNAinsight amendment panel
- Tempus xG+ (extended hereditary cancers) amendment panel
- Tempus xG+ CancerNext expanded standard panel
- Tempus xG+(extended hereditary cancers) - 88 genes standard panel
- Tempus xM next personal DX amendment panel
- Tempus xM next personal DX standard panel
- Tempus xM original panel
- Tempus xR RNA sequence amendment panel
- Tempus xT MMR amendment panel
- Tempus xT PD-L1 28-8 amendment panel
- Tempus xT tumor origin amendment panel

Medications

Additions

- AXN-2510 invest IV
- Compound Salicylic Acid 3% and Clindamycin 2.26% Topical Cream
- Glycine/Sermorelin Acetate Home Kit Subcutaneous
- JNJ-90014496 invest IV
- Low dose naltrexone (LDN) Oral
- Neoantigen Synthetic Long Peptide Vaccine invest Intramuscular
- NRM-823 invest Subcutaneous
- Pyridoxine Hydrochloride/Semaglutide Subcutaneous
- Pyridoxine Hydrochloride/Tirzepatide Subcutaneous
- Rondecabtagene autoleucel (ronde-cell; LYL314) invest IV
- Study Drug invest Pyelocalyceal [antineoplastic]
- TAR-210 (500 mg erdafitinib per TAR-210-C) invest Intravesical
- UGN-104 invest Intra-pyelocalyceal

Updates

Medications	Updates
cosibelimab-ipdl IV	<p>New Instructions:</p> <ul style="list-style-type: none"> • Infuse using an in-line or add-on filter (0.2 to 0.22 micron). • Gently invert to mix. Do not shake. Do not give IV push or bolus. Do not administer with other drugs. <p>New default SIG:</p> <ul style="list-style-type: none"> • 1,200 mg intravenously Piggyback once; administer over 60 minutes; admixture fluid 250 ml • New Maximum Single Dose: • 1,200 mg
Fentanyl Transdermal Patch 25 mcg/hr	<p>Default SIG updated to 3 patches/10 days:</p> <ul style="list-style-type: none"> • 1 patch transdermally every 72 hours. Dispense 3 Patch, quantity sufficient for 10 days <p>Available SIG option for 10 patches/30 days:</p> <ul style="list-style-type: none"> • Fentanyl Patch 1 patch transdermally every 72 hours; quantity sufficient for 30 days <p>Note: The option for 10 patches per 30 days will be available, and practices can set this as the default at their practice level, if desired.</p>
Fentanyl Transdermal Patch 75 mcg/hr	<p>Available SIG option for 10 patches/30 days:</p> <ul style="list-style-type: none"> • Fentanyl Patch 1 patch transdermally every 72 hours; quantity sufficient for 30 days <p>Note: The option for 10 patches per 30 days will be available, and practices can set this as the default at their practice level, if desired.</p>

Medications	Updates
Firmonertinib invest Oral	<p>Updated Category to:</p> <ul style="list-style-type: none"> • Therapeutic <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg orally daily • 0 mg orally daily; Should be taken orally once daily on an empty stomach—no food for at least 2 hours before and 1 hour after dosing. Take at the same time each day with water only (no caffeine). Swallow tablets whole; do not chew, cut, or crush; quantity • 0 mg/kg orally As Directed • 0 mg/m² orally As Directed
Girdestrant invest Oral	<p>Form set to Supplied by Sponsor and or Placebo:</p> <ul style="list-style-type: none"> • 30 mg capsule (also for Research)
Givinostat invest Oral	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg orally As Directed • 0 mg/m² orally As Directed • 0 mg orally 2 times per day • 50 mg orally daily • 75 mg orally daily • 100 mg orally daily
IBI363 invest IV	<p>Removed SIG:</p> <ul style="list-style-type: none"> • 0 mcg/kg intravenously once; Dilute with 0.9% Sodium Chloride to a final concentration of 0.02-0.8 mg/mL. Administer through 0.2-5.0 um in-line filter. Do not shake the vial <p>New Form available:</p> <ul style="list-style-type: none"> • 60 mg/6 mL (10 mg/mL) solution (also for Research)

Medications	Updates
pembrolizumab-berahyaluronidase-pmph Subcutaneous 395 mg-4,800 unit/2.4 mL	New Quick SIG Pick available: <ul style="list-style-type: none"> • 395 mg subcutaneously once
pembrolizumab-berahyaluronidase-pmph Subcutaneous 790 mg-9,600 unit/4.8 mL	New Quick SIG Pick available: <ul style="list-style-type: none"> • 790 mg subcutaneously once
Prednisolone Ophthalmic Drops 1 %	New default Form is set to: <ul style="list-style-type: none"> • 1 % drops,suspension • New Quick SIG Pick available: • 1 drop into the eye(s) 4 times per day • 1 drop into the eye(s) 6 times per day • 1 drop into the eye(s) As Directed • 1 drop into the eye(s) every hour
Tocilizumab IV	No Maximum Single Dose is set. New SIGs with Dose Cap: <ul style="list-style-type: none"> • Tocilizumab 8 mg/kg intravenously Piggyback once; For COVID-19 (SIG contains dose override setting) • Tocilizumab 8 mg/kg intravenously Piggyback once; For Cytokine Release Syndrome (SIG contains dose override setting) • Tocilizumab 8 mg/kg intravenously Piggyback once; For Giant Cell Arteritis (SIG contains dose override setting) • Tocilizumab 6 mg/kg intravenously Piggyback once; For Rheumatoid Arthritis (SIG contains dose override setting)

Medications	Updates
Tocilizumab-aazg IV	<p>New SIGs with Dose Cap:</p> <ul style="list-style-type: none"> • Tocilizumab-anoh 8 mg/kg intravenously Piggyback once; For COVID-19 (SIG contains dose override setting) • Tocilizumab-anoh 8 mg/kg intravenously Piggyback once; For Cytokine Release Syndrome (SIG contains dose override setting) • Tocilizumab-anoh 8 mg/kg intravenously Piggyback once; For Rheumatoid Arthritis (SIG contains dose override setting) • Tocilizumab-anoh 6 mg/kg intravenously Piggyback once; For Giant Cell Arteritis (SIG contains dose override setting)
Tocilizumab-anoh IV	<p>New SIGs with Dose Cap:</p> <ul style="list-style-type: none"> • Tocilizumab-anoh 8 mg/kg intravenously Piggyback once; For COVID-19 (SIG contains dose override setting) • Tocilizumab-anoh 8 mg/kg intravenously Piggyback once; For Cytokine Release Syndrome (SIG contains dose override setting) • Tocilizumab-anoh 8 mg/kg intravenously Piggyback once; For Rheumatoid Arthritis (SIG contains dose override setting) • Tocilizumab-anoh 6 mg/kg intravenously Piggyback once; For Giant Cell Arteritis (SIG contains dose override setting) <p>New Instructions:</p> <ul style="list-style-type: none"> • Dilute to a total volume of 100 mL for patients 30 kg or greater or 50 mL for patients less than 30 kg. Gently invert to mix. Do not shake. Allow diluted solution to warm to room temperature prior to infusion. Do not give IV push or bolus. Do not administer with other drugs. Monitor for infusion reactions. • Note: This is Avtozma.

Medications	Updates
Tocilizumab-bavi IV	<p>New SIGs with Dose Cap:</p> <ul style="list-style-type: none"> • Tocilizumab-bavi 8 mg/kg intravenously Piggyback once; For COVID-19 (SIG contains dose override setting) • Tocilizumab-bavi 8 mg/kg intravenously Piggyback once; For Cytokine Release Syndrome (SIG contains dose override setting) • Tocilizumab-bavi 8 mg/kg intravenously Piggyback once; For Rheumatoid Arthritis (SIG contains dose override setting) • Tocilizumab-bavi 6 mg/kg intravenously Piggyback once; For Giant Cell Arteritis (SIG contains dose override setting) <p>No Maximum Single Dose is set.</p>
TOS-358 invest Oral	<p>Suppressed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg orally As Directed • 0 mg/m² orally As Directed <p>Removed Instructions:</p> <ul style="list-style-type: none"> • Take at the same time daily. Swallow whole—do not chew, crush, or split. Do not retake if vomiting occurs. Follow patient guidelines provided.

Please see [Appendix A](#) for a complete summary of changes.

Regimen Library

Additions

Regimen Name	Diagnosis
Enfortumab vedotin-ejfv D1,8 + Pembrolizumab SQ Q21D	Bladder Cancer; Renal Pelvis and Ureter Cancer; Urethral Cancer
Enzalutamide + Radium-223	Prostate Cancer

Regimen Name	Diagnosis
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Zolbetuximab-clzb Q14D (C1 Split Dosing)	Esophageal Cancer (Parent); Gastric Cancer
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) Q14D (3 mo)	Rectal Cancer
Modified R-CODOX-M	Lymphoma, Non-Hodgkin (NHL) (Parent)
Nivolumab (3 mg/kg) + Ipilimumab (1 mg/kg) C1 D1,22,43,64 (Q21D) fb 6wk break fb Nivolumab C2+ D1,29,57 (Q28D) Maintenance Q84D (Melanoma)	Melanoma, Skin
Palbociclib D1-21 Q28D (Uterine Sarcoma)	Uterine Cancer (Parent)
Pembrolizumab SQ Q21D	Cutaneous Carcinoma, Squamous Cell ; Solid Tumors (Parent) (excluding HL/NHL/ including Solid Other)
Pembrolizumab + Cisplatin + RT Q21D fb Pembrolizumab Q21D (Adjuvant Head and Neck)	Head and Neck Cancer (Parent)
Pembrolizumab + RT Q21D fb Pembrolizumab Q21D (Adjuvant Head and Neck)	Head and Neck Cancer (Parent)
Pembrolizumab SQ + Axitinib Q21D	Renal Cell Carcinoma (RCC)
Pembrolizumab SQ + Carboplatin + Fluorouracil CIV D1-4 Q21D (Part 1 of 2)	Head and Neck Cancer (Parent)
Pembrolizumab SQ + Cisplatin D1,8,15 + XRT Q21D (Cervical)	Cervical Cancer
Pembrolizumab SQ Q21D (Neoadjuvant/Adjuvant Melanoma, Adjuvant Bladder, RCC, NSCLC)	Bladder Cancer; Renal Pelvis and Ureter Cancer; Urethral Cancer ; Lung Cancer, Non-small Cell (NSCLC); Melanoma, Skin; Renal Cell Carcinoma (RCC)
Pembrolizumab SQ + Gemcitabine D1,8 + Cisplatin D1,8 Q21D (Bile Duct)	Bile Duct Cancer (Parent)
Pembrolizumab SQ + Lenvatinib Q21D	Bile Duct Cancer (Parent); Gallbladder Cancer; Melanoma, Skin; Renal Cell Carcinoma (RCC); Uterine Cancer (Parent)
Pembrolizumab SQ + Paclitaxel + Carboplatin Q21D	Lung Cancer, Non-small Cell (NSCLC)

Regimen Name	Diagnosis
Pembrolizumab SQ + Paclitaxel + Carboplatin + Bevacizumab Q21D (Cervical)	Cervical Cancer
Pembrolizumab SQ + Paclitaxel + Carboplatin Q21D (Cervical, Uterine)	Cervical Cancer; Uterine Cancer (Parent)
Pembrolizumab SQ + Paclitaxel + Carboplatin Q21D (Head and Neck) (Part 1 of 2)	Head and Neck Cancer (Parent)
Pembrolizumab SQ + Paclitaxel D1,8,15 + Carboplatin D1,8,15 Q21D fb Pembrolizumab SQ + Doxorubicin + Cyclophosphamide (AC) Q21D	Breast Cancer
Pembrolizumab SQ + Paclitaxel D1,8,15 + Carboplatin Q21D fb Pembrolizumab SQ + Doxorubicin + Cyclophosphamide (AC) Q21D	Breast Cancer
Pembrolizumab SQ + Pemetrexed + Carboplatin Q21D	Lung Cancer, Non-small Cell (NSCLC)
Pembrolizumab SQ + Pemetrexed Maintenance Q21D	Lung Cancer, Non-small Cell (NSCLC)
Pembrolizumab SQ Q21D (Adjuvant Breast)	Breast Cancer
Pembrolizumab SQ Q42D	Cutaneous Carcinoma, Squamous Cell; Solid Tumors (Parent) (excluding HL/NHL/ including Solid Other)
Pembrolizumab SQ Q42D (Adjuvant Melanoma, Bladder, RCC, NSCLC)	Bladder Cancer; Lung Cancer, Non-small Cell (NSCLC); Melanoma, Skin; Renal Cell Carcinoma (RCC); Renal Pelvis and Ureter Cancer; Urethral Cancer
Pembrolizumab Q21D (Neoadjuvant Head and Neck)	Head and Neck Cancer (Parent)
Revumenib Q30D (weight less than 40 kg WITH concomitant strong CYP3A4 inhibitor)	Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myeloid (AML)
Revumenib Q30D (weight less than 40 kg WITHOUT concomitant strong CYP3A4 inhibitor)	Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myeloid (AML)
Rilzabrutinib Q28D (ITP)	Immune Thrombocytopenia Purpura (ITP)

Updates

Biosimilar Precheck Changes

The iKnowMed regimen updates for the remaining biosimilar regimens are now active, following the top 130 utilized regimens activated in September.

- **Nyvepria®** will be replaced with **Fulphila®**
- **Ruxience®** will be replaced with **Truxima®**
- **Trazimera®** will be replaced with **Ogivri®**
- **Zirabev®** will be replaced with **Vegzelma®**

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Bladder Cancer
- Brain Tumor (Parent)
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Crohn's Disease
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gastric Cancer
- Gestational Trophoblastic Tumor
- Head and Neck Cancer (Parent)
- Hemolytic Anemia
- Hodgkin Lymphoma (HL)
- Immune Thrombocytopenia Purpura (ITP)
- Leukemia, Acute Lymphocytic (ALL)
- Leukemia, Acute Myeloid (AML)
- Leukemia, Chronic Lymphocytic (CLL)
- Leukemia, Chronic Myeloid (CML)
- Leukemia, Hairy Cell
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Lymphoma, Hodgkin (HL)
- Melanoma, Mucosal, Head and Neck

- Melanoma, Skin
- Multiple Myeloma (MM)
- Myelodysplastic Syndrome (MDS)
- Myelofibrosis
- Neuroendocrine Tumor, Carcinoid (Parent)
- Ovarian and Primary Peritoneal Cancer
- Pancreatic Cancer, Carcinoid/Neuroendocrine
- Paroxysmal Nocturnal Hemoglobinuria
- Prostate Cancer
- Rectal Cancer
- Renal Cell Carcinoma (RCC)
- Renal Pelvis and Ureter Cancer
- Sarcoma, Soft Tissue (Parent)
- Testicular Cancer (Parent)
- Thymoma, Malignant
- Ulcerative Colitis
- Urethral Cancer
- Uterine Cancer (Parent)
- Waldenstrom's Macroglobulinemia

Renames

Previous Name	New Name
Degarelix D1 Q28D	Degarelix Q28D
Elranatamab-bcmm (Elrexio) SQ D1,8,15,22 fb D1,15 Q28D (Maintenance)	Elranatamab-bcmm (Elrexio) SQ D1,8,15,22 fb D1,15 fb D1 Q28D (Maintenance)
Fluorouracil CIV D1-5 + Cisplatin + Trastuzumab IV Q21D	Fluorouracil CIV D1-4 + Cisplatin + Trastuzumab IV Q28D
Fluorouracil CIV D1-5 + Cisplatin Q21D (Gastric, Esophageal)	Fluorouracil CIV D1-4 + Cisplatin Q28D (Gastric, Esophageal)
Mirvetuximab soravtansine-gynx Q21D	Mirvetuximab soravtansine-gynx (Elahere) Q21D
Nivolumab D1,15,29 + Ipilimumab Q42D (Esophageal, Gastric)	Nivolumab (240 mg) D1,15,29 + Ipilimumab (1 mg/kg) Q42D (Esophageal, Gastric, Uterine, Uterine Sarcoma)
Vorinostat	Vorinostat Q30D

Removals

Regimen Name	Diagnosis
Doxorubicin + Cyclophosphamide (AC) Q21D fb Docetaxel + Pertuzumab IV + Trastuzumab IV Q21D	Breast Cancer
Doxorubicin + Cyclophosphamide (AC) Q21D fb Docetaxel + Trastuzumab IV Q21D	Breast Cancer
Epirubicin D1,2 + Ifosfamide D1-5 Q21D	Sarcoma, Soft Tissue (Parent)
Fludarabine D1-5 + Rituximab IV Q28D	Waldenstrom's Macroglobulinemia
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) D1,15,29 + Zolbetuximabclzb D1,22 Q42D	Esophageal Cancer (Parent), Gastric Cancer
Idelalisib + Bendamustine D1,2 + Rituximab IV Q28D	Leukemia, Chronic Lymphocytic (CLL), Lymphoma, Non-Hodgkin (NHL) (Parent)
Polatuzumab vedotin D2 + Rituximab IV D1 + CHP D1 Q21D (6 cycles) (Immunotherapy Split) fb Rituximab IV Q21D (2 cycles)	Polatuzumab vedotin C1 D2 fb C2-6 D1 + Rituximab IV + CHP Q21D (6 cycles) (C1 Immunotherapy Split) fb Rituximab IV Q21D (2 cycles)
Rituximab IV + Cladribine SQ D1-5 Q28D (Waldenstroms)	Waldenstrom's Macroglobulinemia

NDC – HCPCS Crosswalk

Additions

Medication (Brand)	HCPCS Codes	NDC
Carboplatin IV	J9999 per 1 mg	83831-0141-08

Billing & HCPCS Codes

Updates

Medication	HCPCS Codes
Carboplatin IV	J9999 per 1 mg
COVID vaccine (Moderna) (PF) IM (12 yrs & older) (Mnexspike)	91323 per 0.2 mL
denosumab-bbdz Subcutaneous (60 mg/mL - Jubbonti)	Q5136 per 1 mg
denosumab-nxxp Subcutaneous (60 mg/mL - BILDYOS)	J3590 per 60 mg
denosumab-nxxp Subcutaneous (120 mg/1.7 mL - Bilprevda)	J3590 per 120 mg
elamipretide Subcutaneous	J3490 per 280 mg
immune globulin,gamma(IgG)-dira (PF) IV	J3590 per 500 mg
Nalmefene IM	J3490 per: <ul style="list-style-type: none"> • 2 mg • 2000 mcg
nalmefene IM Auto-Injector	J3490 per 1.5 mg
Nalmefene IV	J3490 per 2000 mcg
Nalmefene Subcutaneous	J3490 per: <ul style="list-style-type: none"> • 2 mg • 2000 mcg
nalmefene Subcutaneous Auto-Injector	J3490 per 1.5 mg
pembrolizumab-berahyaluronidase-pmph Subcutaneous 395 mg-4,800 unit/2.4 mL	J9999 per: <ul style="list-style-type: none"> • 2.4 mL • 395 mg
pembrolizumab-berahyaluronidase-pmph Subcutaneous 790 mg-9,600 unit/4.8 mL	J9999 per: <ul style="list-style-type: none"> • 4.8 mL • 790 mg
tocilizumab-anoh IV	J3590 per 1 mg
zopapogene imadenovec-drba Subcutaneous	J3590 per 5 x 10e11 particle unit

Appendix A

SCRI Medication Updates

Medications	Updates
AAA601 (Lutetium Lu-177 Dotatate) invest IV	Updated Name to: <ul style="list-style-type: none"> [177Lu] Lu-DOTA-TATE invest IV Removed SIGs: <ul style="list-style-type: none"> 0 GBq intravenously once 0 MBq intravenously once 200 mCi intravenously once 7.4 GBq intravenously As Directed; administer 4 times every 8 (+/- 1) weeks
AAA817 invest (225Ac Ac-PSMA-617 invest IV)	Removed Instructions: <ul style="list-style-type: none"> See Pharmacy Manual for preparation, handling, and administration, observation guidance. Removed SIGs: <ul style="list-style-type: none"> 0 MBq/kg intravenously As Directed 0 MBq/m2 intravenously As Directed 0 mCi/kg intravenously As Directed 0 mCi/m2 intravenously As Directed 0 mCi intravenously every 8 weeks 0 MBq intravenously every 8 weeks
AB680 invest IV	Updated Form from 107.5 mg recon soln to: <ul style="list-style-type: none"> 107.5 lyophilized powder for injection vial Removed SIGs: <ul style="list-style-type: none"> 0 mg/mkg intravenously As Directed 0 mg/m2 intravenously As Directed 0 mL intravenously once Removed Instructions: <ul style="list-style-type: none"> Administer 30 minutes (+/- 5 minutes)

Medications	Updates
ABBV-101 invest Oral	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m2 orally daily <p>Removed Formula Units:</p> <ul style="list-style-type: none"> • mg/kg • mg/m2
ABBV-291 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • This product is light sensitive upon reconstitution and dilution. All precautions must be taken to limit light exposure after reconstitution. During infusion, infusion bag covers must be implemented. <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/m2 intravenously As Directed • 0 mg intravenously every 28 days
ABBV-399 invest IV	<p>Updated Form from 100 mg recon soln to:</p> <ul style="list-style-type: none"> • 100 mg lyophilized powder vial <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg intravenously once; Administer over approximately 30 minutes once every 21 days (Q21D). ABBV-399 must be refrigerated at 2 to 8 degrees C/36 to 46 degree Fahrenheit, protected from light • 0 mg/kg intravenously once
ABBV-400 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, and administration, observation guidance. <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg intravenously Infusion (Drip) every 3 weeks • 0 mg/kg intravenously Piggyback once • 0 mg intravenously Piggyback every 4 weeks • 0 mg intravenously Infusion (Drip) every 2 weeks • 0 mg intravenously As Directed

Medications	Updates
AK117 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> Administer over 120 +/- 15 minutes. <p>Removed SIG:</p> <ul style="list-style-type: none"> 0 mg/m² intravenously once; administer over 120 +/- 15 minutes. <p>Removed Formula Units:</p> <ul style="list-style-type: none"> mg/kg
AMG 509 invest IV	<p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg/kg intravenously once 0 mg/m² intravenously As Directed 0 mg intravenously once
APG-2575 invest Oral	<p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg/kg orally daily 0 mg/m² orally daily 0 mg orally daily 0 mg orally 2 times per day
APVO436 invest IV	<p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg intravenously once 0 mcg/kg intravenously once 0 mcg/m² intravenously once 0 mcg intravenously As Directed <p>Removed Instructions:</p> <ul style="list-style-type: none"> DO NOT administer APVO436 as an intravenous bolus or subcutaneously. Infuse over 4 hours
AU-007 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> See Pharmacy Manual for preparation, handling, and administration, observation guidance. <p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg/kg intravenously every 2 weeks 0 mg/m² intravenously every 2 weeks 0 mg intravenously As Directed

Medications	Updates
AVZO-021 (ARTS-021) invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/day orally daily • 0 mg/kg orally daily • 0 mg/m² orally daily
AVZO-1418 invest IV	Removed Instructions: <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, and administration, observation guidance. Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg intravenously every 21 days; Dilute to a final concentration of 0.5 mg/mL to 6 mg/mL. 1st infusion over about 90 minutes; if no infusion reactions, subsequent infusions may be given over 30 to 60 minute IV infusion.; admixture fluid 0 ml of Dextro • 0 mg/kg intravenously every 28 days; Dilute to a final concentration of 0.5 mg/mL to 6 mg/mL. 1st infusion over about 90 minutes; if no infusion reactions, subsequent infusions may be given over 30 to 60 minute IV infusion.; admixture fluid 0 ml of Dextro • 0 mg/kg intravenously once • 0 mg intravenously once • 0 mg/m² intravenously As Directed
AZD8205 invest IV	Removed SIGs: <ul style="list-style-type: none"> • 0 mg intravenously As Directed • 0 mg/kg intravenously every 3 weeks • 0 mg/m² intravenously once
Azenosertib invest (ZN-c3 invest Oral)	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m² orally daily
BAT8006 invest IV	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg intravenously once • 0 mg intravenously once

Medications	Updates
BCA101 invest IV	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg intravenously once; administer over 120 minutes (-10/+20 min); admixture fluid 250 ml • 0 mg/kg intravenously once • 0 mg/m² intravenously once
BI 770371 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, and administration, observation guidance. <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg intravenously once • 0 mg/m² intravenously As Directed • 0 mg intravenously every 3 weeks; administer over 60 min (-5 min/+10 min)
BL-M11D1 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • Administered intravenously for 120 min (+/-10 min). If no infusion reaction occurred during the first administration, the drug could be administered between 60-120 min during subsequent cycles. • See Pharmacy Manual for preparation, handling, and administration, observation guidance. <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg intravenously once • 0 mg/m² intravenously As Directed
BMS-986365 (CC-94676) invest Oral	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m² orally As Directed
BMS-986369/CC-99282 invest Oral	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • Take with or without food. <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m² orally daily • 0 mg orally daily • 0 mg orally As Directed

Medications	Updates
BMS-986489 (BMS-986012 (Atigotatug)-Nivolumab FDC) invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, and administration, observation guidance. <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg intravenously once • 8 mL intravenously every 28 days • 8 mL intravenously every 4 weeks
BMS-986489 invest or Atezolizumab invest IV	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg intravenously once • 0 mg/kg intravenously As Directed • 0 mg/m² intravenously As Directed
BMS-986504 invest Oral	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg orally daily; Take with at least 240 mL (8 oz) of water. Swallow whole; do not chew. • 0 mg/kg orally As Directed • 0 mg/m² orally As Directed
BNT323/DB-1303 invest IV	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/m² intravenously As Directed • 0 mg/kg intravenously once • 0 mg intravenously once
BNT324 (DB-1311) invest IV	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg intravenously every 3 weeks • 0 mg/kg intravenously every 3 weeks • 0 mg/m² intravenously As Directed <p>New SIG:</p> <ul style="list-style-type: none"> • 3 mg/kg intravenously once
BNT327 or Atezolizumab invest IV	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg intravenously once • 0 mg/m² intravenously once

Medications	Updates
CB-010 invest IV	<p>Removed Unit:</p> <ul style="list-style-type: none"> • x 10e6 viable CARpos cells <p>New SIGs:</p> <ul style="list-style-type: none"> • 13 x 10e6 cells/mL intravenously once • 40 x 10e6 cells/mL intravenously once • 60 x 10e6 cells/mL intravenously once • 80 x 10e6 cells/mL intravenously once • 120 x 10e6 cells/mL intravenously once • 360 x 10e6 cells/mL intravenously once
CC-92480 invest Oral	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg orally once • 0 mg/m2 orally once • 0 mg orally daily • 0 mg orally once
CHS-114 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • Do not shake. • Admixture fluid 0.9 % Sodium Chloride <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg intravenously once • 0 mg/m2 intravenously once • 0 mg intravenously every 21 days • 0 mg intravenously every 3 weeks
CRB-601 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • Administer over 30 (+/- 5) minutes. <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/m2 intravenously once • 0 mg intravenously As Directed
Darovasertib invest (IDE196 invest Oral)	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg orally 2 times per day • 0 mg/m2 orally 2 times per day

Medications	Updates
DB-1311 invest IV	<p>Updated Form from 200 mg recon soln to:</p> <ul style="list-style-type: none"> • 200 mg/vial <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg intravenously every 21 days • 0 mg/kg intravenously every 3 weeks
DCC-3014 invest Oral	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • Take whole with a 6 oz (180 mL) glass of water. <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg orally As Directed • 0 mg/m² orally every week • 0 mg orally 2 times per week
DR-0202 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, and administration, observation guidance. <p>Updated Form from 120 mg recon soln to:</p> <ul style="list-style-type: none"> • 120 mg/vial <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg intravenously every 28 days • 0 mg/m² intravenously every 4 weeks • 0 mg intravenously once
DS-6000a invest IV	<p>Updated Form from 100 mg recon soln to:</p> <ul style="list-style-type: none"> • 100mg/ lyophilized powder/ vial <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/m² intravenously As Directed • 0 mg/kg intravenously Piggyback once • 0 mg/kg intravenously Infusion (Drip) once • 0 mg/mg intravenously As Directed • 0 mg intravenously once

Medications	Updates
Elranatamab invest Subcutaneous	Removed Instructions: <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, and administration, observation guidance. Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg intravenously every 4 weeks • 0 mg/m2 intravenously every 2 weeks
Enzomenib invest (DSP-5336 invest Oral)	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally 2 times per day • 0 mg/m2 orally 2 times per day
FX-909 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m2 orally daily • 0 mg orally daily • 0 mg orally As Directed
Givinostat invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg intravenously As Directed • 0 mg/m2 intravenously As Directed
HER3-DXd invest IV	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/m2 intravenously every 3 weeks • 0 mg/kg intravenously every 3 weeks • 0 mg intravenously once

Medications	Updates
HLX22 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, and administration, observation guidance. <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg intravenously once • 0 mg/m2 intravenously As Directed • 0 mg intravenously once • 15 mg/kg intravenously every 3 weeks <p>New SIG:</p> <ul style="list-style-type: none"> • 15 mg/kg intravenously once
HQP1351 invest Oral	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/m2 orally As Directed • 0 mg/kg orally As Directed
Hydrocortisone Emergency Kit	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg intramuscularly once • 0 mg orally once • 0 kits orally As Directed <p>New Instructions available:</p> <ul style="list-style-type: none"> • Each kit includes: Hydrocortisone 10 mg tablets (1 bottle of 100 tablets) and hydrocortisone 100 mg powder and solution (for IM injection). <p>Removed Routes:</p> <ul style="list-style-type: none"> • Orally • Intramuscularly <p>New Route:</p> <ul style="list-style-type: none"> • As directed

Medications	Updates
<p>IBI3009 invest IV</p>	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/m2 intravenously once • 0 mg/kg intravenously every 2 weeks • 0 mg/m2 intravenously every 3 weeks <p>Updated Form:</p> <ul style="list-style-type: none"> • Lyophilized powder <p>Removed Instructions:</p> <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, and administration, observation guidance.
<p>IFx-Hu2.0 invest Intralesional</p>	<p>New Route:</p> <ul style="list-style-type: none"> • Intratumoral <p>Removed Instructions:</p> <ul style="list-style-type: none"> • Refer to Pharmacy Manual for preparation instructions. <p>Updated Form:</p> <ul style="list-style-type: none"> • Kit (2 vials/kit); Vial 1: pAc/emm55 0.6 mg/0.3 mL soln and Vial 2: in vivo-jetPEI 1.71 mg/0.6 mL soln = Final Vial IFx-Hu2.0 0.6mg/1.2 mL <p>Removed SIG:</p> <ul style="list-style-type: none"> • 1.2 mL intralesionally As Directed <p>New SIG:</p> <ul style="list-style-type: none"> • 0.2 mL intratumorally once

Medications	Updates
Igrelimogene Litadenorepvec invest (TILT-123 invest IV)	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 x 10e11 vp intravenously every 3 weeks • 0 x 10e12 vp intravenously once • 1 x 10e11 vp intravenously once • x 10e11 vp intravenously once • 3.3 x 10e11 vp intravenously once <p>Added SIGs:</p> <ul style="list-style-type: none"> • 1 x 10e11 intravenously once <ul style="list-style-type: none"> ○ x 10e11 intravenously once • 3.3 x 10e11 intravenously once • 1 x 10e12 intravenously once <ul style="list-style-type: none"> ○ x 10e12 intravenously once • 3.3 x 10e12 intravenously once <p>Removed Instructions:</p> <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, and administration, observation guidance.
Izalontamab Brengitecan invest (BMS-986507 invest IV)	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg intravenously As Directed • 0 mg/kg intravenously once • 0 mg/m2 intravenously once <p>Updated Form:</p> <ul style="list-style-type: none"> • mg/vial <p>Removed Instructions:</p> <ul style="list-style-type: none"> • Do not shake. See Pharmacy Manual for preparation, handling, and administration, observation guidance.

Medications	Updates
<p>JSB462 invest Oral</p>	<ul style="list-style-type: none"> • Removed Instructions: Swallow whole with food. <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg orally As Directed • 0 mg/m² orally As Directed • 0 mg orally daily <p>New SIG:</p> <ul style="list-style-type: none"> • 200 mg orally daily
<p>JZP815 invest Oral</p>	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg intravenously As Directed • 0 mg/kg intravenously once • 0 mg/m² intravenously once <p>Updated Form:</p> <ul style="list-style-type: none"> • mg/vial <p>Removed Instructions:</p> <ul style="list-style-type: none"> • Do not shake. See Pharmacy Manual for preparation, handling, and administration, observation guidance.
<p>KB707 invest Intratumoral</p>	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mL intratumorally once • 0 x 10⁹ pfu intratumorally once • 0 x 10⁹ pfu/mL intratumorally once <p>Added SIG:</p> <ul style="list-style-type: none"> • 2 mL intratumorally once

Medications	Updates
<p>KITE-772 invest IV</p>	<p>Updated Medication Name to:</p> <ul style="list-style-type: none"> • Anitocabtagene Autoleucel invest IV <p>Updated Form from 10-15 cryostorage bag to:</p> <ul style="list-style-type: none"> • Cryostorage bag <p>Removed Instructions:</p> <ul style="list-style-type: none"> • Must be administered through dimethyl sulfoxide (DMSO) compatible IV tubing. • See Pharmacy Manual for preparation, handling, and administration, observation guidance.
<p>KQB198 invest Oral</p>	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m² orally daily • 0 mg orally As Directed • 0 mg orally daily

Medications	Updates
LOXO-435 invest Oral	<p>Removed SIGs:</p> <ul style="list-style-type: none">• 0 mg orally daily• 140 mg orally 2 times per day; For BID dosing schedule, take doses approximately 12 hours apart.• 20 mg orally 2 times per day; For BID dosing schedule, take doses approximately 12 hours apart.• 200 mg orally 2 times per day; For BID dosing schedule, take doses approximately 12 hours apart.• 300 mg orally 2 times per day; For BID dosing schedule, take doses approximately 12 hours apart.• 40 mg orally 2 times per day; For BID dosing schedule, take doses approximately 12 hours apart.• 400 mg orally 2 times per day; For BID dosing schedule, take doses approximately 12 hours apart.• 800 mg orally 2 times per day; For BID dosing schedule, take doses approximately 12 hours apart. <p>New SIGs:</p> <ul style="list-style-type: none">• 40 mg orally daily• 80 mg orally daily• 140 mg orally daily• 200 mg orally daily• 300 mg orally daily• 400 mg orally daily• 6 mg orally 2 times per day• 12 mg orally 2 times per day• 20 mg orally 2 times per day• 40 mg orally 2 times per day• 80 mg orally 2 times per day• 140 mg orally 2 times per day• 200 mg orally 2 times per day• 300 mg orally 2 times per day• 400 mg orally 2 times per day <p>Removed Instructions:</p> <ul style="list-style-type: none">• To be taken at same time each day with water. Take under fasting conditions, at least 2 hours before and 1 hour after dose.

Medications	Updates
MK-5684 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally 2 times per day • 0 mg/m2 orally 2 times per day
MRTX1719 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally As Directed • 0 mg/m2 orally As Directed
Nemtabrutinib invest (MK-1026 invest Oral)	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m2 orally daily
NMS-03597812 invest Oral	Removed Instructions: <ul style="list-style-type: none"> • Must not be taken with antacids or with food. Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m2 orally daily
NVL-655 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m2 orally daily
Olomorasib invest (LY3537982 invest Oral)	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally 2 times per day • 0 mg/kg orally As Directed • 0 mg/kg orally daily
ONO-4578 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally 2 times per day • 0 mg/m2 orally As Directed • 0 mg orally daily
OP-1250 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m2 orally daily

Medications	Updates
ORIC-944 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally As Directed • 0 mg/m2 orally once
Pasritamig (JNJ-78278343) invest IV	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg intravenously As Directed • 0 mg/m2 intravenously once • 0 mg intravenously once
Patritumab Deruxtecan (MK-1022) invest (HER3-DXd invest IV)	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/m2 intravenously ever 3 weeks
PC14586 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m2 orally daily
PDS0101 (Versamune and HPVmix) invest Subcutaneous	Removed Instructions: <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, and administration, observation guidance. Removed SIG: <ul style="list-style-type: none"> • 0 mg subcutaneously As Directed
PF-07248144 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally As Directed • 0 mg/m2 orally As Directed • 0 mg orally daily
Pirtobrutinib invest (LOXO-305 invest Oral)	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally As Directed • 0 mg/m2 orally As Directed • 0 mg orally daily
PRO1184 invest IV	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg intravenously As Directed • 0 mg intravenously As Directed

Medications	Updates
PT199 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> Administer over a minimum of 2 hours (+/- 20 minutes). See Pharmacy Manual for preparation, handling, and administration, observation guidance. <p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg/m² intravenously As Directed 0 mg/kg intravenously every week 0 mg intravenously every 3 weeks
REGN1979 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> See Pharmacy Manual for preparation, handling, and administration, observation guidance. <p>Updated Form to:</p> <ul style="list-style-type: none"> 20 mg/mL vial 2 mg/mL vial <p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg/kg intravenously once 0 mg/m² intravenously once 0 mg intravenously once
REGN3767-REGN2810 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> Refer to dose preparation table in the pharmacy manual. <p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg/kg intravenously As Directed 0 mg/m² intravenously As Directed 0 mL intravenously every 3 weeks 0 mg intravenously Infusion (Drip) every 21 days 0 mg intravenously Infusion (Drip) every 3 weeks

Medications	Updates
REGN7075 invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> See Pharmacy Manual for preparation, handling, and administration, observation guidance. <p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg/kg intravenously As Directed 0 mg/m² intravenously As Directed 0 mg intravenously once
Rilvegostomig (AZD2936) 750 mg or Pembrolizumab 200 mg invest IV	<p>Removed Instructions:</p> <ul style="list-style-type: none"> See Pharmacy Manual for preparation, handling, and administration, observation guidance. <p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg intravenously every 21 days 0 mg intravenously every 3 weeks
Rilvegostomig invest (AZD2936 invest IV)	<p>Updated Form:</p> <ul style="list-style-type: none"> 750 mg/vial (50 mg/mL) <p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg intravenously As Directed 0 mg intravenously once 0 mg/kg intravenously once 0 mg/m² intravenously once
RLY-2608 invest Oral	<p>Removed Instructions:</p> <ul style="list-style-type: none"> Take with food and with approximately 240 mL (8 oz) of water. <p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg/kg orally As Directed 0 mg/m² orally As Directed 0 mg orally 2 times per day

Medications	Updates
RO7198457 invest IV	Removed SIGs: <ul style="list-style-type: none"> • 0 mcg/kg intravenously As Directed • 0 mcg/m2 intravenously As Directed Removed Instructions: <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, administration, and observation guidance.
RO7435846 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m2 orally daily • 0 mg orally daily
RP1-104 invest Intratumoral	Removed Instructions: <ul style="list-style-type: none"> • The maximum volume of VO to be injected into any patient on any injection day will be 10 mL.
RYZ101 invest IV	Removed SIGs: <ul style="list-style-type: none"> • 0 MBq/kg intravenously once • 0 kBq intravenously once • 0 kBq/kg intravenously once • 0 uCi intravenously once • 0 uCi intravenously every 6 weeks • 0 uCi/kg intravenously once
Sacituzumab Tirumotecan invest (MK-2870 invest IV)	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/m2 intravenously once
Serabelisib invest Oral	Removed Instructions: <ul style="list-style-type: none"> • Take with food Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally As Directed • 0 mg/m2 orally As Directed

Medications	Updates
SGN-B7H4V invest IV	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/m² intravenously once • 0 mg/kg intravenously once • 0 mg/kg intravenously every 3 weeks • 0 mg/kg intravenously every 4 weeks • 0 mg/kg intravenously As Directed • 0 mg intravenously once
Sigvotatug Vedotin invest (SGN-B6A invest IV)	Removed SIGs: <ul style="list-style-type: none"> • 1.8 mg/kg AIBW intravenously once
STAR0602 invest IV	Updated Form from 10 mg/mL (5 mL vial) solution to: <ul style="list-style-type: none"> • 10 mg/mL vial Removed SIGs: <ul style="list-style-type: none"> • 0 mg/m² intravenously once • 0 mg/kg intravenously every 2 weeks • 0 mg/kg intravenously every 3 weeks • 0 mg/kg intravenously every 6 weeks • 0 mg intravenously As Directed
STRO-002 invest IV	New Forms available: <ul style="list-style-type: none"> • 10 mg/mL solution • 100 mg lyophilized powder
TAK-079 invest Subcutaneous	Updated Form from 150 mg/mL soln 2 mL vials/kit to: <ul style="list-style-type: none"> • 2ml vials = 1 kit Removed Instructions: <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, and administration, observation guidance. Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg subcutaneously once • 0 mg/m² subcutaneously once • 0 kits subcutaneously once • 600 mg subcutaneously every week

Medications	Updates
TERN-701 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally As Directed • 0 mg/m2 orally As Directed
TNG260 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally As Directed • 0 mg/m2 orally 2 times per day
TORL-1-23 invest IV	Removed Instructions: <ul style="list-style-type: none"> • Administer via a 30 minute (+/- 10 min) IV infusion Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg intravenously every 3 weeks • 0 mg/m2 intravenously As Directed • 0 mg intravenously once
TOS-358 invest Oral	Removed Instructions: <ul style="list-style-type: none"> • To be taken at same time each day with water. Take under fasting conditions, at least 2 hours before and 1 hour after dose. For BID dosing schedule, take doses approximately 12 hours apart.
TT-00420 invest Oral	Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m2 orally daily
TUB-040 invest IV	Removed Instructions: <ul style="list-style-type: none"> • See Pharmacy Manual for preparation, handling, and administration, observation guidance. Updated Form from 60 mg recon soln to: <ul style="list-style-type: none"> • 60 mg/10 mL lyophilized powder Removed SIGs: <ul style="list-style-type: none"> • 0 mg/kg intravenously every 21 days; administer over 30 minutes • 0 mg/m2 intravenously As Directed • 0 mg intravenously As Directed

Medications	Updates
VNX-101 (AAVrh.74hCD19/CD3-scFv) invest IV	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mL intravenously once • 0 vials intravenously once • 0 x 10e10 vg/kg intravenously once • 0 x 10e11 vg/kg intravenously once • 0 x 10e12 vg/kg intravenously once <p>Removed Instructions:</p> <ul style="list-style-type: none"> • Administer over 60-75 minutes <p>Updated Form:</p> <ul style="list-style-type: none"> • 4.56x10¹² vg/mL per 2.3 mL vial
VT3989 invest Oral	<p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg orally daily • 0 mg/m² orally As Directed
Vusolimogene Oderparepvec invest (RP1-104 invest Intratumoral)	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • Withdraw required amount directly from glass vial via syringe of appropriate sizing. Administration amount will depend on longest lesion diameter. No requirement for reconstitution. • The maximum volume of VO to be injected into any patient on any injection day will be 10 mL. The maximum concentration of VO to be injected into any patient will be 1 × 10⁷ PFU/mL (nominal). <p>Updated Instructions:</p> <ul style="list-style-type: none"> • Withdraw required amount directly from glass vial via syringe of appropriate sizing. Administration amount will depend on longest lesion diameter. No requirement for reconstitution. Maximum concentration injected into any patient will be 1x10⁷ PFU/mL.
WSD0922-FU invest Oral	<p>Removed Instructions:</p> <ul style="list-style-type: none"> • Tablets can be taken whole with approximately 240 mL water without food (at least 60 minutes before food and at least 2 hours after food). <p>Removed SIGs:</p> <ul style="list-style-type: none"> • 0 mg/kg orally As Directed • 0 mg/m² orally daily

Medications	Updates
<p>WTX-124 invest IV</p>	<p>Removed Instructions:</p> <ul style="list-style-type: none"> Administer by IV infusion over 15 minutes via syringe pump. <p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg/kg intravenously As Directed 0 mg/m² intravenously As Directed <p>Removed Frequency:</p> <ul style="list-style-type: none"> Every 2 weeks <p>Updated Form from 30 mg recon soln to:</p> <ul style="list-style-type: none"> 30 mg lyophilized powder
<p>ZL-1310 invest IV</p>	<p>Removed Instructions:</p> <ul style="list-style-type: none"> See Pharmacy Manual for preparation, handling, and administration, observation guidance. <p>Removed SIGs:</p> <ul style="list-style-type: none"> 0 mg/kg intravenously every 3 weeks; administer over 60 minutes (+/- 10 mins) 0 mg/m² intravenously once 0 mg intravenously As Directed 2 mg/kg intravenously once <p>New SIG available:</p> <ul style="list-style-type: none"> 1.2 mg/kg intravenously once